Conference item
SCALOP-2: A multi-centre randomised study of induction chemotherapy followed by capecitabine (+/- nelfinavir) with high or standard dose radiotherapy for locally advanced non-metastatic pancreatic cancer
- Abstract:
- Chemotherapy followed by consolidation chemoradiotherapy (CRT) is a treatment option for locally advanced non-metastatic pancreatic cancer (LAPC), but outcome remains poor. The SCALOP trial identified a feasible, safe, and effective CRT regimen for LAPC: capecitabine (830mg/m2 oral bd) as radiosensitisation + 50.4Gy in 28 fractions. The two-stage SCALOP-2 trial aims to improve this regimen by increasing radiotherapy dose intensity and adding nelfinavir as an additional radiosensitising AKT inhibitor.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Accepted manuscript, pdf, 446.0KB)
-
- Publisher copy:
- 10.1093/annonc/mdx262.026
Authors
Bibliographic Details
- Publisher:
- Oxford University Press Publisher's website
- Host title:
- 19th World Congress on Gastrointestinal Cancer
- Journal:
- 19th World Congress on Gastrointestinal Cancer 2017 Journal website
- Publication date:
- 2017-06-26
- Acceptance date:
- 2017-04-24
- DOI:
Item Description
- Pubs id:
-
pubs:691019
- UUID:
-
uuid:06e219dc-1d45-496b-a853-bc9aff80b62f
- Local pid:
- pubs:691019
- Source identifiers:
-
691019
- Deposit date:
- 2017-04-24
Terms of use
- Copyright holder:
- Virdee et al
- Copyright date:
- 2017
- Notes:
- © The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For Permissions, please email: journals.permissions@oup.com. This is the accepted manuscript version of the article. The final version is available online from Oxford University Press at: https://doi.org/10.1093/annonc/mdx262.026
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record